title: Treatment of canine intervertebral disc displacement with chondroitinase ABC.
abstract: METHODS
  This study demonstrated the therapeutic value of chemonucleolysis with chondroitinase ABC to canine intervertebral disc displacement.
  
  
  OBJECTIVE
  To determine the efficacy of Chondroitinase ABC in the management of canine intervertebral disc displacement.
  
  
  BACKGROUND
  No previous study has assessed the chemonucleolysis with chondroitinase ABC in the displaced discs. The changes of intervertebral disc syndrome were evaluated in this study.
  
  
  METHODS
  Fifty-nine dogs with symptoms and signs of intervertebral disc displacement were treated with Chondroitinase ABC by a single intradisc injection. The changes in symptoms and signs of disc herniation in the dogs were followed from 7 days to 3 years after treatment.
  
  
  RESULTS
  Forty-eight dogs were evaluated for the efficacy of the chemonucleolytic treatment with chondroitinase ABC. At 1 week after injection, 45 of 48 dogs showed some improvement in symptoms and signs. No adverse reactions were observed. There was no recurrence of symptoms in nine dogs who were observed from 14 months to 3 years after injection.
  
  
  CONCLUSIONS
  Chemonucleolytic treatment with chondroitinase ABC is an effective and safe method for the management of canine intervertebral disc displacement.
authors.affiliation: Tokyo Research Institute, Seikagaku Corporation, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Nakayama
authors.forename: S
authors.initials: S
authors.lastname: Chimura
authors.forename: K
authors.initials: K
authors.lastname: Nakahara
authors.forename: M
authors.initials: M
authors.lastname: Morozumi
authors.forename: K
authors.initials: K
authors.lastname: Horie
authors.forename: Y
authors.initials: Y
authors.lastname: Fujita
authors.forename: T
authors.initials: T
authors.lastname: Hirose
mesh_terms: D000818:Animals; D002574:Cervical Vertebrae / Q000187:drug effects / Q000473:pathology; D002808:Chondroitin Lyases / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D005260:Female; D015552:Injections, Intralesional / Q000662:veterinary; D007404:Intervertebral Disc Chemolysis / Q000662:veterinary*; D007405:Intervertebral Disc Displacement / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D008159:Lumbar Vertebrae / Q000187:drug effects / Q000473:pathology; D008297:Male; D013122:Spinal Diseases / Q000188:drug therapy / Q000473:pathology; D013904:Thoracic Vertebrae / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D002808:Chondroitin Lyases